CHICAGO - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term results from the CHRYSALIS study, which showed the combination of RYBREVANT (amivantamab-vmjw) and lazertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was associated with sustained antitumor activity as a first-line treatment in patients with EGFR-mutated non-small cell lung cancer (NSCLC) (Abstract #9134).

These findings and additional data, including an analysis of predictive biomarkers from Cohort D of the Phase 1/1b CHRYSALIS-2 study evaluating a chemotherapy-free regimen of RYBREVANT in combination with lazertinib (Abstract #9013)2 and updated safety results from the Phase 1 PALOMA study evaluating the subcutaneous (SC) administration of RYBREVANT as a monotherapy (Abstract #9126)3 were presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Patients enrolled in the treatment-naive cohort from the ongoing CHRYSALIS (NCT02609776) study had NSCLC characterized by either an EGFR exon 19 deletion (ex19del) (n=11) or L858R mutation (n=9).1,4 After a median follow-up of nearly three years (33.6 months), the median duration of response (DOR), median progression-free survival (PFS) and overall survival (OS) were not yet reached. The estimated PFS rate was 85 percent after one year, 65 percent at two years and 51 percent at three years. The longest ongoing duration of treatment is over three years (37.2 months), and longest DOR is nearly three years (35.7 months).1

Safety among patients in this cohort was consistent with previous reports and no new safety signals were identified. Treatment-related dose interruptions, reductions and discontinuations of either RYBREVANT or lazertinib occurred in seven patients (35 percent), eight patients (40 percent) and one patient (5 percent), respectively.1

'Advanced NSCLC and EGFR-mutated lung cancer has a five-year survival rate of less than 20 percent, underscoring an urgent need for more targeted treatment options, especially in earlier lines of therapy,' said Se-Hoon Lee, M.D., Ph.D., professor of medicine at the Samsung Medical Center and Sungkyunkwan University School of Medicine, and presenting author. 'These long-term data for amivantamab and lazertinib introduce the potential for this combination therapy to be used as first-line treatment for this patient population.'

New Analyses on Predictive Biomarkers for Response to RYBREVANT and Lazertinib Combination Therapy

Patients with advanced NSCLC harboring common EGFR mutations including ex19del or L858R who have experienced disease progression on or after osimertinib are a population with substantial unmet medical need. There are no approved targeted therapies, and the standard of care is platinum-doublet chemotherapy. Data from Cohort D of the Phase 1/1b CHRYSALIS-2 study, which enrolled such patients, were highlighted in an oral presentation at ASCO this year. CHRYSALIS-2 (NCT04077463) is an open-label study to evaluate the safety and pharmacokinetics of lazertinib as monotherapy or in combination with RYBREVANT.5 Consistent with a prior presentation at ASCO 2021, these data indicate that immunohistochemical (IHC) staining (a testing method using antibodies to determine the relative level of certain antigens or markers in cancer tissue samples) for MET may identify patients more likely to benefit from treatment with the combination of RYBREVANT and lazertinib.2,6 Among patients with MET overexpression as identified by immunohistochemistry, the response rate was 61 percent with a median PFS of 12.2 months. In contrast, patients with low MET expression had a response rate of 14 percent with a median PFS of 4.2 months.

Updated Safety Data from the Phase 1 PALOMA Study Evaluating the Investigational Use of Subcutaneous RYBREVANT

Results from the Phase 1 PALOMA study were featured in a poster presentation and showed RYBREVANT SC dose was administered on the first day in less than seven minutes, removing the need for split dosing.3 The current approved RYBREVANT intravenous (IV) infusion dosing is split over two days, with infusion times of approximately 4 to 6 hours for the RYBREVANT 1050 mg and 1400 mg dose, respectively.8 PALOMA (NCT04606381) is an ongoing, open-label, multicenter study assessing the investigational SC administration of RYBREVANT as a potential treatment for patients with advanced NSCLC.7 Meaningful reductions in the incidence and severity of infusion related reactions (IRRs) were also observed (16 percent [no grade 3 or higher IRR] with SC as compared to 67 percent [two percent grade 3 or higher IRR] previously reported with IV).3

'These data provide further evidence of the potential efficacy and safety profile of RYBREVANT as both monotherapy and combination therapy for the treatment of patients with EGFR-mutated NSCLC and support our commitment to advance personalized treatment regimens in areas of continued unmet need,' said Kiran Patel, M.D., Vice President, Clinical Development, Solid Tumors, Janssen Research & Development, LLC. 'We look forward to continuing to evaluate the full potential of RYBREVANT in our ambition to make this novel therapy available earlier in the treatment paradigm for these patients and improve cancer care.'

About the CHRYSALIS Study

CHRYSALIS (NCT02609776) is a Phase 1 open-label, multicenter, first-in-human study to evaluate the safety, pharmacokinetics and preliminary efficacy of RYBREVANT as a monotherapy and in combinations including with lazertinib, a novel third-generation EGFR TKI, in adults with advanced NSCLC. The study consists of two parts: RYBREVANT monotherapy and combination dose escalations (Part 1) and RYBREVANT monotherapy and combination dose expansions (Part 2). The study enrolled 780 patients with advanced NSCLC.4

The treatment-naive cohort of the ongoing CHRYSALIS study enrolled patients with EGFR ex19del or L858R-mutated advanced NSCLC. All patients received 1050 mg of RYBREVANT intravenously (1400 mg if weighing at least 80 kg or more) and 240 mg of lazertinib orally. Disease response using overall response rate (ORR), per Response Evaluation Criteria in Solid Tumors Version 1.1t (RECIST v1.1) as evaluated by Blinded Independent Central Review (BICR), was the primary endpoint. Circulating tumor DNA was analyzed from plasma samples prior to initiation of treatment, at Cycle 3 Day 1, and at end of treatment.1

About the CHRYSALIS-2 Study5

CHRYSALIS-2 (NCT04077463) is an open-label Phase 1/1b study to evaluate the safety and pharmacokinetics of lazertinib, a third generation EGFR-TKI, as monotherapy or in combinations with RYBREVANT, a human bispecific EGFR and cMet antibody in participants with advanced NSCLC. The study enrolled 460 patients with advanced NSCLC.

Cohort D of the ongoing CHRYSALIS-2 study seeks to validate one or both potential biomarker strategies (NGS and IHC), previously identified in Cohort E, in patients with osimertinib-relapsed and chemotherapy-naive, EGFR ex19del or L858R-mutated NSCLC. Patients receive the recommended Phase 2 dose of lazertinib orally once daily and RYBREVANT every seven days for the first 28-day cycle and every two weeks thereafter.

About the PALOMA Study7

PALOMA (NCT04606381) is a Phase 1, open-label, multicenter study assessing the feasibility of the SC administration of RYBREVANT based on safety and pharmacokinetics, and to determine a dose, dose regimen and formulation for RYBREVANT SC delivery.

In the ongoing PALOMA study, patients with various advanced solid tumors must have progressed after standard-of-care therapy for metastatic disease, be ineligible for, or have declined current standard therapies. In Part 1, the feasibility of SC administration of RYBREVANT using the available intravenous (IV) formulation (50 mg/mL) at the recommended Phase 2 dose for IV administration, with and without recombinant human hyaluronidase (rHuPH20), will be assessed. In Part 2, dose escalation will be evaluated using a high-concentration formulation (160 mg/mL) of RYBREVANT, with and without rHuPH20. This study is also evaluating administration of the full dose of RYBREVANT on the first day.

About RYBREVANT

RYBREVANT (amivantamab-vmjw) received accelerated approval by the U.S. Food and Drug Administration (FDA) in May 2021 for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.8 This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. RYBREVANT has also received approval from health authorities in Europe, as well as other markets around the world.

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer prefer NGS-based strategies over PCR-based approaches for the detection of EGFR exon 20 insertion variants and include amivantamab-vmjw (RYBREVANT) as a subsequent therapy option with a Category 2A recommendation for patients that have progressed on or after platinum-based chemotherapy with or without immunotherapy and have EGFR exon 20 insertion mutation-positive advanced NSCLC.9(+)^

RYBREVANT is being studied in multiple clinical trials in NSCLC, including: As first-line therapy in the Phase 3 MARIPOSA (NCT04487080) study assessing RYBREVANT in combination with lazertinib, a novel third generation EGFR TKI, versus osimertinib and versus lazertinib alone in untreated advanced EGFR-mutated NSCLC.10

The Phase 3 MARIPOSA-2 (NCT04988295) study assessing the efficacy of RYBREVANT (with or without lazertinib) and carboplatin-pemetrexed versus carboplatin-pemetrexed in patients with locally advanced or metastatic EGFR ex19del or exon 21 L858R substitution NSCLC after osimertinib failure.11

The Phase 1 CHRYSALIS (NCT02609776) study evaluating RYBREVANT in participants with advanced NSCLC.4

The Phase 1/1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT in combination with lazertinib and lazertinib as a monotherapy in patients with advanced NSCLC with EGFR mutations.5

The Phase 3 PAPILLON (NCT04538664) study assessing RYBREVANT in combination with carboplatin-pemetrexed versus chemotherapy alone in patients with advanced or metastatic EGFR-mutated NSCLC and exon 20 insertion mutations.12

The Phase 1 PALOMA (NCT04606381) study assessing the feasibility of subcutaneous (SC) administration of RYBREVANT based on safety and pharmacokinetics and to determine a dose, dose regimen and formulation for RYBREVANT SC delivery.7

The Phase 2 PALOMA-2 (NCT05498428) study assessing subcutaneous RYBREVANT in participants with advanced or metastatic solid tumors including EGFR-mutated NSCLC.13

The Phase 3 PALOMA-3 (NCT05388669) study assessing lazertinib with subcutaneous RYBREVANT as compared to intravenous RYBREVANT in participants with EGFR-mutated advanced or metastatic NSCLC.14

The Phase 1/2 METalmark (NCT05488314) study assessing RYBREVANT and capmatinib combination therapy in unresectable metastatic NSCLC.15

About Lazertinib

Lazertinib is an oral, third-generation, brain-penetrant EGFR TKI that targets both the T790M mutation and activating EGFR mutations while sparing wild type-EGFR. Integrated analysis of the efficacy and safety of lazertinib from the Phase 1/2 study were published in The Journal of Thoracic Oncology in 2022.16 In 2018, Janssen Biotech, Inc. entered into a license and collaboration agreement with Yuhan Corporation for the development of lazertinib.

About Non-Small Cell Lung Cancer

Worldwide, lung cancer is one of the most common cancers, with NSCLC making up 80 to 85 percent of all lung cancer cases.17,18 The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma and large cell carcinoma.19 Among the most common driver mutations in NSCLC are alterations in EGFR, which is a receptor tyrosine kinase supporting cell growth and division.20 EGFR mutations are present in 10 to 15 percent of people with NSCLC adenocarcinoma and occur in 40 to 50 percent of Asians.19-25 EGFR ex19del or EGFR L858R mutations are the most common EGFR mutations.26 The five-year survival rate for all people with advanced NSCLC and EGFR mutations treated with EGFR TKIs is less than 20 percent.27,28

About the Janssen Pharmaceutical Companies of Johnson & Johnson

At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology and Pulmonary Hypertension.

Cautions Concerning Forward-Looking Statements

This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of RYBREVANT (amivantamab-vmjw) and lazertinib and RYBREVANT SC. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research and Development, LLC, Janssen Biotech, Inc., any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A.

Contact:

Suzanne Frost

Tel: +1 416-317-0304

(C) 2023 Electronic News Publishing, source ENP Newswire